



Recommended COVID-19 vaccines for **people who ARE moderately or severely immunocompromised, aged 6 months–4 years, mRNA vaccines, with vial icons and dosages, May 2023\***





\*For product- and vaccination history-specific dosages, administration intervals, and additional dose information, see [Table 2](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**

- Moderna
- Pfizer-BioNTech
- Moderna **OR** Pfizer-BioNTech

Recommended COVID-19 vaccines for **people who ARE moderately or severely immunocompromised, aged 5 years, mRNA vaccines, with vial icons and dosages, May 2023\***



\*For administration intervals, additional dose information, and options for heterologous dosing, see [Table 2](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.


**Key**

Moderna

Pfizer-BioNTech

Moderna **OR** Pfizer-BioNTech

Recommended COVID-19 vaccines for **people who ARE moderately or severely immunocompromised, aged 6–11 years, mRNA vaccines, with vial icons and dosages, May 2023\***



\*For product-specific dosages, administration intervals, additional dose information, and options for heterologous dosing, see [Table 2](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.



**Key**

Moderna

Pfizer-BioNTech

Moderna **OR** Pfizer-BioNTech

Recommended COVID-19 vaccines for **people who ARE moderately or severely immunocompromised, aged 12 years and older, mRNA vaccines, with vial icons and dosages, May 2023\***



\*For administration intervals, additional dose information, and options for heterologous dosing, see [Table 2](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.



**Key**

Moderna

Pfizer-BioNTech

Moderna **OR** Pfizer-BioNTech

# Recommended COVID-19 vaccines for people who ARE moderately or severely immunocompromised, aged 6 months–4 years, mRNA vaccines, May 2023\*





\*For product- and vaccination history-specific dosages, administration intervals, and additional dose information, see [Table 2](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**

- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech

# Recommended COVID-19 vaccines for people who ARE moderately or severely immunocompromised, aged 5 years, mRNA vaccines, May 2023\*




\*For product- and vaccination-history-specific dosages, administration intervals, additional dose information, and options for heterologous dosing, see [Table 2](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**

- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech

# Recommended COVID-19 vaccines for people who ARE moderately or severely immunocompromised, aged 6 years and older, mRNA vaccines, May 2023\*



\*For product-specific dosages, administration intervals, additional dose information, and options for heterologous dosing, see [Table 2](#) in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**

- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech